Glioblastoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Temozolomide monotherapy Variant #13 | — | R 8 153 | 28d | ~4.0 mo | ~16.6 mo | ~5 | ~R 40 764 PFS proxy · indirect | 7 |
Temozolomide and low-dose RT Variant #01 | — | R 7 338 | 21d | — | ~9.3 mo | — | — | 1 |
Radiation therapy N/A - radiation Partial | — | — | 49d | — | ~7.5 mo | — | — | 7 |
3 of 3 regimens shown